Editions Ecce Terra CAMPARIS electron GFP microprobe facility Microscopie Confocale

Laboratoire de Microsondes Chromogenic in situ hybridization (CISH) – Microscope Electronique à Balayage

fallback-image

Ruxolitinib Invivogen

Lab Reagents

Human IgG antibody Laboratories manufactures the ruxolitinib invivogen reagents distributed by Genprice. The Ruxolitinib Invivogen reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact InVivoGen. Other Ruxolitinib products are available in stock. Specificity: Ruxolitinib Category: Invivogen

Chemicals information

Ruxolitinib (free base)

10-042 25 mg
EUR 348.5
Description: Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19).

Ruxolitinib . phosphate salt

10-043 25 mg
EUR 323.3
Description: Water-soluble phosphate salt of Ruxolitinib. Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19)

Ruxolitinib (JAK kinase inhibitor)

SIH-509-25MG 25 mg
EUR 625
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml).

Ruxolitinib (JAK kinase inhibitor)

SIH-509-5MG 5 mg
EUR 238
Description: The substance Ruxolitinib is a jak kinase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is off-white solid which is soluble in DMSO (25 mg/ml) or EtOH (~15 mg/ml).

Recent Posts

August 2022
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  

Categories

Tags